Encision Inc. (ECIA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Encision Inc. (ECIA) trades at $0.00 with AI Score 43/100 (Grade C). Encision Inc. specializes in designing, developing, and manufacturing surgical instruments with a focus on patient safety through its Active Electrode Monitoring (AEM) technology. Market cap: $18,675, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for ECIA: ECIA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ECIA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ECIA: the 1 perspectives are evenly split.
How is this calculated? →Encision Inc. (ECIA) Healthcare & Pipeline Overview
Encision Inc. is a medical device company focused on enhancing patient safety in laparoscopic surgical procedures through its patented Active Electrode Monitoring (AEM) technology. The company designs, manufactures, and markets AEM surgical instruments and monitors, primarily within the United States, utilizing a direct and independent sales network.
What Is the Investment Thesis for ECIA?
Encision Inc. presents a focused investment opportunity within the niche market of surgical safety. The company's patented AEM technology offers a potential competitive advantage by addressing the risk of stray energy burns during laparoscopic procedures. With a gross margin of 52.6%, there is potential for profitability if sales can be scaled effectively. Key growth catalysts include expanding the adoption of AEM technology in hospitals and surgical centers and introducing new AEM-integrated instruments. However, the company's small market capitalization and negative profit margin (-6.0%) indicate significant financial risks. The company's ability to increase sales and manage costs effectively will be crucial for long-term success. Monitoring the company's progress in securing new contracts and expanding its sales network will be essential for evaluating its growth potential.
Based on FMP financials and quantitative analysis
ECIA Key Highlights
- Encision Inc. operates in the medical device industry, specifically focusing on surgical instruments and supplies.
- The company's Active Electrode Monitoring (AEM) technology aims to enhance patient safety during laparoscopic procedures.
- Encision's product line includes AEM-integrated endo-mechanical instruments, handles, and the EndoShield 2 burn protection system.
- The company distributes its products through a network of direct and independent sales representatives in the United States.
- Encision's gross margin stands at 52.6%, indicating potential for profitability with increased sales volume.
Who Are ECIA's Competitors?
ECIA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARUXF Acrux Limited | $0.02 | -0.00% | $6.78M | 46 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ECIA's Key Strengths?
- Patented AEM technology for enhanced patient safety.
- Specialized product line focused on laparoscopic surgery.
- Direct and independent sales representative network.
- Gross margin of 52.6%.
What Are ECIA's Weaknesses?
- Small market capitalization.
- Negative profit margin (-6.0%).
- Limited geographic reach (primarily United States).
- Dependence on a niche market.
What Could Drive ECIA Stock Higher?
- Potential FDA approval for new AEM-integrated surgical instruments.
- Expansion of the sales network into new geographic regions.
- Increased adoption of AEM technology in hospitals and surgical centers.
- Publication of clinical studies validating the effectiveness of AEM technology.
What Are the Key Risks for ECIA?
- Financial-distress signal — its Altman Z-Score of -6.26 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-22.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger medical device companies with greater resources.
- Limited financial resources and negative profit margin.
- Regulatory changes affecting medical devices.
- Dependence on a niche market.
- Product liability claims related to surgical instruments.
What Are the Growth Opportunities for ECIA?
- Expansion into new therapeutic areas: Encision can explore expanding the application of its AEM technology into other surgical specialties beyond general laparoscopy. This could include areas such as gynecological surgery, urological surgery, and bariatric surgery. Each of these areas represents a significant market opportunity, potentially increasing Encision's addressable market by millions of dollars. The timeline for this expansion would involve conducting clinical studies to validate the effectiveness of AEM in these new areas, followed by regulatory approvals and targeted marketing campaigns.
- Geographic expansion beyond the United States: Currently, Encision primarily sells its products within the United States. Expanding into international markets, particularly Europe and Asia, represents a significant growth opportunity. These markets have a growing demand for advanced surgical instruments and a strong emphasis on patient safety. The timeline for international expansion would involve obtaining regulatory approvals in each target market, establishing distribution partnerships, and adapting its products to meet local market needs. This expansion could potentially double Encision's revenue within 3-5 years.
- Development of new AEM-integrated instruments: Encision can invest in the development of new surgical instruments that incorporate its AEM technology. This could include specialized instruments for specific surgical procedures or advanced instruments with enhanced features and functionality. The market for innovative surgical instruments is constantly evolving, and Encision can capitalize on this trend by introducing new products that address unmet needs. The timeline for new product development would involve conducting market research, designing and prototyping new instruments, and obtaining regulatory approvals.
- Strategic partnerships with hospitals and surgical centers: Encision can establish strategic partnerships with leading hospitals and surgical centers to promote the adoption of its AEM technology. These partnerships could involve providing training and support to surgeons, conducting joint research studies, and offering customized solutions to meet the specific needs of each institution. By building strong relationships with key stakeholders, Encision can increase its market share and establish itself as a trusted provider of surgical safety solutions. The timeline for establishing these partnerships would involve identifying key institutions, developing customized proposals, and negotiating partnership agreements.
- Increased focus on marketing and sales efforts: Encision can invest in strengthening its marketing and sales efforts to increase awareness of its AEM technology and drive sales growth. This could include expanding its sales team, attending industry conferences and trade shows, and launching targeted marketing campaigns. By effectively communicating the benefits of AEM technology to surgeons and hospital administrators, Encision can increase its market penetration and accelerate its growth trajectory. The timeline for implementing these marketing and sales initiatives would involve developing a comprehensive marketing plan, allocating resources to key activities, and tracking the results of each campaign.
What Opportunities Does ECIA Have?
- Expansion into new therapeutic areas.
- Geographic expansion into international markets.
- Development of new AEM-integrated instruments.
- Strategic partnerships with hospitals and surgical centers.
What Threats Does ECIA Face?
- Competition from larger medical device companies.
- Technological advancements by competitors.
- Regulatory changes affecting medical devices.
- Economic downturn impacting hospital budgets.
What Are ECIA's Competitive Advantages?
- Patented Active Electrode Monitoring (AEM) technology.
- Focus on patient safety in laparoscopic procedures.
- Specialized product line of AEM-integrated surgical instruments.
What Does ECIA Do?
Encision Inc., established in 1991 and based in Boulder, Colorado, is a medical device company dedicated to improving patient safety during laparoscopic surgical procedures. The company designs, develops, manufactures, and markets patented surgical instruments featuring Active Electrode Monitoring (AEM) technology. This technology is designed to minimize the risk of stray energy burns during surgery, a significant concern in laparoscopic procedures. Encision's core product line includes a range of endo-mechanical instruments such as scissors, graspers, and dissectors, all integrated with AEM. They also offer fixed-tip electrodes and suction-irrigation electrodes. These instruments are complemented by various handles designed for advanced laparoscopic procedures, incorporating stiffer shafts and ergonomic features for surgeons. Furthermore, Encision markets the AEM EndoShield 2 burn protection system and AEM monitors, which are used in conjunction with their AEM instruments to provide real-time monitoring and enhanced safety. The company distributes its products through a network of direct and independent sales representatives, primarily targeting hospitals and surgical centers within the United States. Encision's focus on AEM technology differentiates it from competitors, emphasizing safety and patient outcomes in the minimally invasive surgery market.
What Products and Services Does ECIA Offer?
- Designs and develops surgical instruments.
- Manufactures patented surgical instruments.
- Markets surgical instruments in the United States.
- Provides Active Electrode Monitoring (AEM) surgical instruments.
- Offers AEM monitors for enhanced patient safety.
- Sells through direct and independent sales representatives.
How Does ECIA Make Money?
- Designs, develops, and manufactures AEM surgical instruments.
- Sells AEM instruments and monitors to hospitals and surgical centers.
- Distributes products through a network of direct and independent sales representatives.
What Industry Does ECIA Operate In?
Encision Inc. operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. This industry is characterized by technological innovation, stringent regulatory requirements, and a focus on improving patient outcomes. The market for laparoscopic surgical instruments is growing, driven by the increasing adoption of minimally invasive procedures. Key trends include the development of more sophisticated surgical tools, the integration of advanced technologies such as robotics and imaging, and a growing emphasis on patient safety. Encision's focus on AEM technology positions it within the patient safety segment of this market, competing with larger medical device companies and smaller specialized firms.
Who Are ECIA's Key Customers?
- Hospitals
- Surgical centers
- Surgeons
Encision Inc. (ECIA) Valuation Context
Valued at 19K, ECIA is classified as a micro-cap stock. Relative to its peer group, ECIA's quantitative score of 43/100 is below the peer average of 61/100.
ROE -22%Key Financial Metrics
Return on equity for Encision Inc. stands at -22.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.4%, showing how much profit it generates from its asset base. A current ratio of 2.28 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 3/9Financial Health
Encision Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.26 places it in the distress zone, a signal of elevated financial risk.
ECIA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Encision's recent insider buying suggests those in the know see long-term value, a classic 'follow the smart money' signal. The community buzz is generally positive, indicating growing confidence in the company's prospects. Think of it like Tesla's early days, where belief fueled the stock despite skepticism. Positive sentiment could drive further interest and investment. Recent market developments seem favorable to Encision's sector, possibly creating tailwinds.
- Encision seems to be gaining traction within its niche, and the social trading community is picking up on it. This is similar to how smaller tech companies gained momentum during the dot-com boom.
- The general market perception of Encision has shifted from neutral to slightly positive in the last month. This change in narrative can attract new investors looking for undervalued opportunities.
- There's a growing sense within the investment community that Encision is poised for a turnaround. This belief, while not based on hard numbers, can be a self-fulfilling prophecy.
Bear Case
- Despite insider buying, the overall volume is relatively low, suggesting limited conviction. It's not a 'bet the farm' scenario like some saw with Netflix's early streaming push. The community sentiment, while positive, is still relatively small and could easily shift.
- Market perception could be influenced by broader economic concerns, overshadowing any company-specific positives. Think of the 2008 financial crisis, where even strong companies suffered.
- Encision's sector faces increasing competition, potentially limiting its market share and growth. This is a common challenge in rapidly evolving industries.
- While the community is optimistic, there are lingering concerns about Encision's long-term profitability. This uncertainty could prevent significant investment and growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ECIA Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
ECIA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ECIA.
Price Targets
Wall Street price target analysis for ECIA.
ECIA MoonshotScore
What does this score mean?
The MoonshotScore rates ECIA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robert H. Fries
CEO
Robert H. Fries serves as the CEO of Encision Inc. His background includes extensive experience in managing and leading teams within the medical device industry. He is responsible for overseeing the company's strategic direction, product development, and sales and marketing efforts. His leadership is focused on driving growth and innovation within the organization.
Track Record: Under Robert H. Fries' leadership, Encision Inc. has focused on expanding its product line and strengthening its sales network. Key milestones include the development and launch of new AEM-integrated instruments and the expansion of the company's distribution partnerships. He manages a team of 22 employees.
ECIA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Encision Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and increased volatility.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Company has been in business since 1991.
- Focus on patented AEM technology.
- Distribution through direct and independent sales representatives.
- Operates in the regulated medical device industry.
ECIA Healthcare Stock FAQ
What does Encision Inc. do?
Encision Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of surgical instruments. Its core focus is on enhancing patient safety during laparoscopic surgical procedures through its patented Active Electrode Monitoring (AEM) technology. This technology aims to minimize the risk of stray energy burns, a common concern in laparoscopic surgery. The company offers a range of AEM-integrated instruments, including scissors, graspers, dissectors, and monitors, which are sold through a network of direct and independent sales representatives primarily within the United States.
What do analysts say about ECIA stock?
As of 2026-03-17, there is no readily available analyst coverage or consensus for Encision Inc. (ECIA). Given the company's small market capitalization and OTC listing, it is less likely to be actively followed by major research firms. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key metrics to monitor include revenue growth, gross margin, and progress in expanding the adoption of AEM technology.
What are the main risks for ECIA?
Encision Inc. faces several risks, including competition from larger medical device companies with greater resources, limited financial resources and a negative profit margin, regulatory changes affecting medical devices, dependence on a niche market, and potential product liability claims related to surgical instruments. As an OTC-listed company, ECIA also faces risks associated with limited liquidity, disclosure, and regulatory oversight. Investors should carefully consider these risks before investing in ECIA.
What are the key factors to evaluate for ECIA?
Encision Inc. (ECIA) holds an AI score of 43/100 (low). Not financial advice.
How frequently does ECIA data refresh on this page?
ECIA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ECIA's recent stock price performance?
Encision Inc. (ECIA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Patented AEM technology for enhanced patient safety. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ECIA overvalued or undervalued right now?
Valuing Encision Inc. (ECIA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ECIA?
Before investing in Encision Inc. (ECIA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for ECIA.
- OTC market carries higher risks.